GSK — GSK plc

—
NYSE · Health Care · Pharmaceuticals · CIK 1131399 · United Kingdom
Last close
$49.24
Market Cap
$98.62B
52W High
$59.57
52W Low
$44.23
ADV30
4,821,901
Next earnings
2026-10-28

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 8,887,000,000 6,497,000,000 2,127,000,000 1,543,000,000 71,699,000,000 2,934,000,000 53,337,000,000
Jun 2026 8,409,000,000 6,143,000,000 481,000,000 435,000,000 61,738,000,000 3,105,000,000 44,561,000,000
Mar 2026 7,629,000,000 5,754,000,000 2,293,000,000 1,737,000,000 62,869,000,000 3,442,000,000 45,447,000,000
Dec 2025 8,618,000,000 5,961,000,000 1,506,000,000 636,000,000 61,118,000,000 3,150,000,000 45,162,000,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$8,918,000,000
Investing CF
$-10,896,000,000
Financing CF
$1,937,000,000
CapEx
$-2,654,000,000
Dividends Paid
$-2,698,000,000
Buybacks
$-886,000,000
EPS Diluted TTM
$2.14
As of
2026-11-08

Balance + Analyst (yfinance extras)

Retained Earnings
$12,458,000,000
Inventory
$6,300,000,000
Receivables
—
ST Investments
$28,000,000
EBIT TTM
$6,125,000,000
Pretax Income TTM
$5,383,000,000
Interest Exp TTM
$742,000,000
Analysts
9

Yahoo Snapshot (yfinance, live)

Total Revenue
$33,202,999,296
EBITDA
$10,817,999,872
Free Cash Flow
$3,482,625,024
Enterprise Value
$111,147,458,560
Total Cash
$3,105,999,872
Total Debt
$18,293,000,192
Shares Out
2,002,805,623
Trailing EPS
$3.19
Book Value
$11.91
ROE
33.4%
ROA
10.0%
Div Yield
3.78%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 32,667,000,000 8,338,000,000 5,716,000,000 61,118,000,000 45,162,000,000 16,377,000,000 7,741,000,000
Dec 2024 31,376,000,000 5,542,000,000 2,575,000,000 59,463,000,000 46,377,000,000 13,671,000,000 6,554,000,000
Dec 2023 30,328,000,000 7,345,000,000 4,928,000,000 59,005,000,000 46,210,000,000 13,347,000,000 6,768,000,000
Dec 2022 29,324,000,000 6,729,000,000 14,956,000,000 60,146,000,000 50,050,000,000 10,598,000,000 7,403,000,000

TTM Snapshot

Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$4.98

Max Pain — expiry 2026-12-11 (volume-derived — Yahoo OI feed degraded)

max pain strike: $51.00 · spot: $48.58 · call volume: 414 · put volume: 43

Peers — same industry

TickerNameMarket CapLastDaily %
REGN REGENERON PHARMACEUTICALS, INC. $97.34B $957.76 —
SNY Sanofi $113.89B $47.53 —
BMY BRISTOL MYERS SQUIBB CO $125.40B $61.35 —
VRTX VERTEX PHARMACEUTICALS INC / MA $135.44B $534.20 —
NVO NOVO NORDISK A S $136.10B $40.70 —

News headlines (Yahoo Finance, 1h cache)

Former Novartis U.S. Chief Strategy Officer Scott Howell, MD, MBA, Joins GOA Therapeutics as Chief Commercial Officer
2026-11-18 18:30 · Yahoo
GSK Wins FDA Approval for Nuvalent-Acquired Nelkarmi in Lung Cancer
2026-11-18 15:35 · Yahoo
GSK CFO Points to Cancer Drugs to Bridge £3.4 Billion Sales Forecast Gap
2026-11-18 02:12 · Yahoo
GSK wins FDA approval for lung cancer drug Nelkarmi
2026-11-17 19:18 · Yahoo
GSK Targets £40 Billion in Sales as HIV Patent Cliff Looms
2026-11-17 10:12 · Yahoo
GSK Accelerates Late-Stage Studies as It Targets COPD and Long-Acting Respiratory Treatments
2026-11-09 19:15 · Yahoo
GSK (LSE:GSK) Stock Still Looks Below Fair Value Following Jemperli Approval
2026-11-06 10:18 · Yahoo
What Does GSK (LSE:GSK) FDA Lung Cancer Approval Change For Investors?
2026-11-19 06:12 · Yahoo
Nelkarmi (neladalkib) approved in the US for previously-treated advanced ALK-positive non-small cell lung cancer
2026-11-17 22:00 · Yahoo
Ziphius, a leading saRNA biotech, today announces the appointment of Mr. Antoon Loomans to its Board of Directors
2026-11-16 13:45 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.